BioScience Trends. 2025;19(5):495-510. (DOI: 10.5582/bst.2025.01292)

Chinese expert consensus on the combined use of antiviral drugs for influenza

Yuan J, Zhang HM, Zou RR, Weng WZ, Bai HL, Chen J, Chong YT, Deng XL, Fu L, Fu YY, Gao WJ, Gong ZJ, Huang CH, Huang H, Huang J, Jiang JN, Jiang RM, Jiang YF, Li LH, Lin BL, Liu X, Lin F, Peng J, Qi QS, Qin B, Qu ZJ, Shi F, Wu G, Wu T, Wang H, Wang LW, Wang Y, Xiao F, Xu F, Xu J, Xu KJ, Zhu HP, Zhou GL, Chen GB, Lu HZ; National Medical Research Center for Infectious Diseases

Influenza is an acute respiratory infectious disease caused by influenza viruses, and it poses a serious threat to global public health. High-risk groups include the elderly, infants and young children, pregnant women, and patients with chronic underlying diseases. These groups are prone to developing severe illness after infection, which can lead to serious complications and even death. Early antiviral treatment is key to reducing the rate of severe illness and death. Currently, authoritative guidelines at home and abroad recommend early, single-agent antiviral therapy as the standard regimen. However, anti-influenza virus monotherapy has problems such as drug resistance and poor therapeutic effect. To address these problems, this consensus was developed by organizing experts from the departments of Infectious Diseases, Respiratory Medicine, Critical Care Medicine, and Pharmacy. These experts systematically sorted out domestic and international evidence on combined antiviral therapy for influenza and formulated expert recommendations on combined antiviral therapy for influenza in specific populations.

Full Text: